Reduce Tobacco Use in People Living With HIV in Switzerland
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Jan 17, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective different products to help quit smoking—like e-cigarettes, nicotine pouches, and nicotine patches—can be for people living with HIV in Switzerland. The goal is to see if these options can help participants stop smoking cigarettes for at least seven days after six months of use. The study is currently recruiting participants aged 18 and older who smoke at least one cigarette a day.
To participate, individuals need to agree to be part of the Swiss HIV Cohort Study and give consent for being randomly assigned to receive one of the smoking cessation products. However, people who are already using e-cigarettes, nicotine pouches, or patches, as well as pregnant women, cannot join the trial. Participants can expect support and guidance as they try to quit smoking, and their progress will be monitored over the six months. This trial aims to find effective ways to help improve the health of smokers living with HIV.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent for the data collection and participation in the SHCS (Cohort consent).
- • Signed informed consent to be randomized to future interventions (Randomization consent).
- • Age 18 years or older.
- • Smoked one or more tobacco cigarettes per day (smoking status = yes) at the time of enrolment.
- Exclusion Criteria:
- • Currently using e-cigarettes or nicotine pouches or nicotine patches.
- • Pregnant women.
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Bern, , Switzerland
Geneva, , Switzerland
St. Gallen, Saint Gallen, Switzerland
Zürich, , Switzerland
Lausanne, Waadt, Switzerland
Patients applied
Trial Officials
Matthias Briel, Prof.
Principal Investigator
University Hospital, Basel, Switzerland
Alain Amstutz, Dr.
Principal Investigator
University Hospital, Basel, Switzerland
Christof Schönenberger, Dr.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported